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Abstract
A simple, rapid and reproducible reversed-phase high-performance liquid chromatography method for the analysis of
nimesulide and its impurities both in the bulk drug and pharmaceutical formulations is reported. The method is suitable
for monitoring the stability of nimesulide. The presence of nimesulide impurities C (2-phenoxyaniline) and D (2-phe-
noxy-4-nitroaniline) was observed. The best separation was achieved using an Agilent Zorbax Extend C18 column (150
× 4.6 mm, particle size 5 µm) at 40 °C and flow rate of 1.0 mLmin–1. The analytes were monitored at 230 nm. The mo-
bile phase consisted of acetonitrile – triethylamine (TEA) – water (45:0.5:54.5 v/v/v), adjusted to pH 5.2 with formic
acid. Under these conditions the retention times were of 7.11, 7.98 and 8.66 min for nimesulide, D and C, respectively.
The resolution of nimesulide and impurity D was 3.20 and that of impurity D and impurity C 2.40, indicating that the
compounds were well separated. Evaluation of linearity, accuracy, precision, selectivity, sensitivity and robustness of
the method produced satisfactory results. The developed method was successfully applied to assay nimesulide in differ-
ent solid pharmaceutical formulations.
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1. Introduction
Tissue injury is associated with the release of 
numerous inflammatory mediators including prostaglan-
dins synthesized from arachidonic acid via endoperoxide
biosynthetic pathway, the initial step being catalyzed by
cyclooxygenase (COX) that appears in two isoforms
COX-1 and COX-2. The latter isoform, representing the
major form of the enzyme is associated with inflammation
and its expression is up-regulated in response to inflam-
matory stimuli in numerous tissues.1,2
Nimesulide (4-nitro-2-phenoxymethanesulfonanilide)
is a selective COX-2 nonsteroidal anti-inflammatory drug.
This compound, a derivative of p-nitrophenylmethane-
sulfonamide, is structurally a unique nonsteroidal anti-in-
flammatory drug. It belongs to selective COX-2 inhibitors,
with a potent anti-inflammatory and analgesic activity, when
administered orally, rectally, or topically.3 Due to its anal-
getic and antipyretic properties, nimesulide is widely used
for the treatment of various inflammatory processes.4
Besides, it is better tolerated and causes fewer adverse ef-
fects than other currently used non-steroidal anti-inflamma-
tory drugs.5 Also, nimesulide seems to express less severe
gastrointestinal side effects. This compound structurally dif-
fers from other new classes of COX-2 inhibitors named cox-
ibes. Chemical structure of nimesulide is given in Fig. a.
Figure a: Chemical structure of nimesulide (4-nitro-2-phenoxy-
methanesulfonanilide).
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The literature data suggest various pKa values (from
5.9 to 6.56) of nimesulide.6 This compound is freely solu-
ble in organic polar solvents, while its solubility in water
was reported to be 0.01 mg mL–1 but it depends on the pH
of the aqueous solution.6
Chemical structure of the main nimesulide impuri-
ties C (2-phenoxyaniline) and D (2-phenoxy-4-nitroani-
line) is presented in Fig. b.
European Pharmacopoeia describes the tests for
numesulide related substances and a potentiometric assay
for nimesulide itself.7 Tests for numesulide impurities C
and D in Ph.Eur. is HPLC method with mobile phase ace-
tonitile:1.15gL–1ammonium dihydrogen phosphate (35:65
v/v) adjusted to pH 7.0 with ammonia. In addition, a refer-
ence on high speed liquid chromatography from 1977,8
and a list of the references for the analysis of nimesulide
by HPLC, the most recent being from 2007,9–30 and by
HPTLC.31–32 are given. It is worth mentioning HPLC and
TLC methods for monitoring photochemical stability of
nimesulide.33 Analytical methods reported for nimesulide
also include UV spectroscopy34 and polarography.35
Up to date, there are several analytical methods for
determination of nimesulide in pharmaceutical dosage
forms, e.g. HPLC,28–29 high-throughput HPLC assay for
nimesulide and its impurities using a short monolithic col-
umn,30 HPTLC,31 spectrophotometric determination of
nimesulide,36 and voltammetric determination of nime-
sulide in pharmaceutical formulations and human serum.37
However, there are no reports on determination of nime-
sulide in the presence of its main impurities C and D in dif-
ferent solid pharmaceutical formulations by HPLC
method. This prompted us to develop a new RP-HPLC
method for simultaneous determination of nimesulide and
its impurities C and D which could be used for the moni-
toring the stability of nimesulide in different solid pharma-
ceutical dosage forms. One of the tested formulations con-
tained β-cyclodextrin. Namely, nimesulide can cause
bioavailability problems in vivo that could be overcome by
the formation of inclusion complexes with β-cyclodex-
trin.38 The novelty of the procedure described here is based
on the presentation of a new, simple, rapid (10 min), reli-
able and sensitive stability-indicating analytical method
which could be helpful in efforts to control the quality of
nimesulide in different solid pharmaceutical formulations.
2. Experimental
2. 1. Chemicals and Reagents
Standards of nimesulide and the impurities were ob-
tained from EDQM, Council of Europe BP 907-F67029
Strasburg CEDEX 1, Batch/Lot no. 1a. TEA and formic
acid (98–100%) of analytical purity were Merck (Darm-
stadt, Germany) products. HPLC gradient-grade acetonitrile
was supplied by Lab Scan (Dublin, Ireland). All other
reagents were of purity grade suitable for high-performance
liquid chromatography. Water for chromatography was ob-
tained from Millipore Simplicity 185 purification system
(Billerica, Massachusetts, USA). Investigated nimesulide
tablets containing 100 mg nimesulide were formulated by
the following pharmaceutical companies: By Zdravlje
Actavis (Serbia) (TENAPROST® containing lactose, maize
starch, povidone K30, magnesium stearate and colloidal an-
hydrous silica as excipients); By Replekpharm (FYR
Macedonia) (VENTOR® with dioctyl sodium sulfosuccinate,
hypromellose, lactose monohydrate, microcrystalline cellu-
lose and sodium starchglycolate as excipients; By Panacea
Biotec (India) (NIMULID® with lactose monohydrate,
crosscarmelose sodium, colloidal anhydrous silica, maize
starch, povidone K30, polysorbate 80 and magnesium
stearate as excipients); By CSC Pharmaceuticals Handels
GmbH (Austria) (AULIN® with hydroxypropyl cellulose,
docusate sodium, lactose, sodium carboxymethylstarch, 
microcrystalline cellulose and magnesium stearate as excip-
ients) and by Habitpharm (Serbia) (NIMESULID with 
β-cyclodextrin, cremophore, microcrystalline cellulose,
sodium starchglycolate, talc, colloidal anhydrous silica,
magnesium stearate and crosspovidone as excipients).
2. 2. Instrumentation 
and Chromatographic Conditions
HPLC analysis was performed with an Agilent
Technologies HP 1100 chromatograph (Palo Alto, CA, USA)
equipped with 1100 binary pump, 1100 UV-visible detector
and 20 µL loop injector. Compounds were separated on an
Agilent Zorbax Extend C18 analytical column (150 × 4.6
mm, particle size 5 µm). Mobile phase and the solutions were
degassed and vacuum filtered through 0.45 µm nylon mem-
branes (Alltech Associates, Loceren, Belgium) before the
use. Data were acquired by ChemStation software from HP.
The mobile phase consisted of acetonitrile – TEA –
water (45:0.5:54.5 v/v/v) and pH adjusted to 5.2 with
formic acid. Isocratic elution was performed at a flow rate
of 1.0 mL min–1 and UV-detection at 230 nm. Before each
injection, the column was equilibrated to stable baseline at
a flow rate of 1.0 mL min–1 and 40 °C.
2. 3. Standard Solutions
The concentrations of nimesulide stock and standard
solutions were 1.0 mg mL–1 and 0.1 mg mL–1, respectively.
Figure b: Chemical structure of nimesulide impurities C (1) 
and D (2).
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Solutions of the examined impurities were prepared
from their own reference standards. Concentration of the
stock solution of impurity C was 0.2 mg mL–1 and stan-
dard solution contained 0.004 mg mL–1. The stock solu-
tion of impurity D contained 0.2 mg mL–1 and standard
solution 0.004 mg mL–1. To prepare standard solutions,
the stock solutions were diluted with the mobile phase. All
prepared solutions were stored light-protected.
For nimesulide standard calibration plot the concen-
trations from 0.016 to 0.160 mg mL–1 were used. Standard
calibration plots for impurities C and D were obtained us-
ing the concentrations from 0.033 to 0.333 µg mL–1.
The solutions of nimesulide and impurities C and D
were stable during the described chromatographic analysis.
2. 3. 1. Sample Preparation
For the assay of nimesulide in dosage forms, 20
tablets from each formulation were randomly selected and
powdered. Amount equivalent to 25 mg nimesulide from
powdered tablets was accurately weighed, transferred into
a volumetric flask, dissolved in approximately 15 mL mo-
bile phase in an ultrasonic bath for 15 min and.the solu-
tion diluted to volume with the same solvent and filtered.
It contained 1.0 mg nimesulide per mL. One mL of this
solution was diluted to 10 mL in a volumetric flask with
the same solvent. Each solution was chromatographed
three times. All solutions were freshly prepared before the
analysis.
3. Results and Discussion
3. 1. Development of the Method 
and Optimization
A new RP-HPLC method for simultaneous determi-
nation of nimesulide and its main impuites C and D has
been developed and evaluated. The RP-HPLC method
was tested for selectivity, linearity, sensitivity, accuracy,
precision and robustness.
Resolution of nimesulide and impurity D, as well as
that of impurity D and impurity C represented the main
problem because of similarity of their chemical structure
and polarity. In initial chromatographic conditions, mobile
phase consisting of acetonitrile-water solution (60 : 40 v/v)
adjusted to pH 4.3 with formic acid and TEA, was used. The
compounds were separated on an Agilent Zorbax Extend
C18 column (150 × 4.6 mm, particle size 5 µm) at ambient
temperature on an Agilent Technologies HP 1100 chromato-
graph equipped with 1100 binary pump at a flow rate of 1.0
mL min–1. The UV-detection was performed at 230 nm.
Under these chromatographic conditions, a satisfactory sep-
aration of mixture compounds was achieved. All three com-
pounds were eluted within 4 min and satisfactory values for
required chromatographic parameters were obtained.
However, when nimesulide in concentration range
present in final pharmaceutical products was chro-
matographed (individual impurities in finished pharma-
ceutical dosage form are allowed to be in quantity up to the
0.2% of the principal quantity),39 nimesulide peak was par-
tially overlapping the peak of impurity D, i.e. a poor sepa-
ration resulted. Combined effects of mobile phase pH,
temperature of the column and acetonitrile content in the
mobile phase on reverse phase liquid chromatographic be-
havior of nimesulide and its impurities were also studied.
Preliminary analyses revealed the following: 1. Lower pH
values of the mobile phase led to a poor separation of im-
purities D and C. In addition, at higher pH values up to the
5.5 of the mobile phase, poorer separation of nimesulide
from impurity D was observed; 2. Reduction of acetoni-
trile content in the mobile phase from 60% to 50% resulted
in a better separation of nimesulide and impurity D, but
poor resolution of impurities D and C. Further decrease of
acetonitrile concentration to 45% provided a satisfactory
separation of nimesulide from impurity D, but, at column
temperature of 30 °C and pH 4.0 of the mobile phase, the
examined impurities were completely overlapped. At pH
4.5 of the mobile phase, the impurities were partially sepa-
rated and the separation was additionally improved in-
creasing temperature of the column. Further increase of the
pH value to 5.0 and column temperature to 40 °C, resulted
in a satisfactory separation of the impurities.
Temperature increase reduced the retention time of
the compounds. Higher temperature values of the column
positively influenced separation of the compounds, regar-
dless of mobile phase acidity and acetonitrile concentra-
tion. For the purpose of lower costs of the method, the
lowest acetonitrile concentration of 45% in the mobile
phase at which a satisfactory separation of the impurities
was achieved, together with the correction of temperature
and pH were applied.
Using a software ChemOffice 7 Ultra, 2002 (Cam-
bridgeSoft Corporation, USA) it was found that nime-
sulide and the impurities D and C had LogP of 3.08, 3.09
and 3.13, respectively, what is in accordance with experi-
mental conditions, as well with the properties of the ex-
amined compounds.
Nimesulide was first eluted from the column, to be
followed by the impurity D and then C. pKa value of
nimesulide was around 6.566. It appeared in the ionized
form at the tested pH values of the mobile phase. Its mol-
ecule has one methylsulfonamide group and one nitro
group in p-position in relation to methylsulfonamide
group. These groups influenced nimesulide polarity and
because of that, it was shortly retained on the nonpolar
stationary phase. Since it was more soluble in the polar
mobile phase used here than the impurities, it was the first
to be eluted from the column, i.e., it had the shortest reten-
tion time. Molecule of the impurity D contains the pri-
mary aromatic amino group instead of methylsulfonamide
group of nimesulide and nitro group in p-position in rela-
plate number (N = 5.54*(tR/Wh)
2) and height equivalent to
one theoretical plate (HETP = L/N) are listed in Table 1.
Tests for selectivity, sensitivity, linearity, accuracy,
precision and robustness of the method afforded satisfac-
tory results. Qualitative comparison of the chromatograms
obtained from standard and sample solutions showed that
the selectivity of the HPLC method described here was
good. Since the excipients did not interfere with the exam-
ined compounds which is shown in Fig. d., the method is
suitable for quality and stability testing of both the active
substance and the final product.
The calibration curves were evaluated by their cor-
relation coefficients. Linearity for nimesulide was asse-
ssed within the concentration range 0.016–0.165 mg mL–1
with correlation coefficient of r = 0.9999. Linearity for
impurities C and D was assessed within the concentration
range 0.033–0.333 µg mL–1 with correlation coefficients
of r = 0.9986 and r = 0.9999, respectively. Regression
lines for nimesulide and the examined impurities were
constructed by the method of the least squares. The results
of the regression analysis of nimesulide, impurity C and
impurity D are summarized in Table 2.
Both limit of detection (LOD) and limit of quantita-
tion (LOQ) were calculated according to the equation:
LOD = 3xSa/a and LOQ = 10xSa/a, where Sa represents
standard deviation of the slope (a). The quantitation limit
for nimesulide was 5.8 µg mL–1. Minimum levels at which
impurity C could be reliably detected and quantified were
0.0044 µg mL–1 and 0.0146 µg mL–1, respectively. The 
detection limit of impurity D was 0.0026 µg mL–1 and the
corresponding quantitation limit 0.0085 µg mL–1. The 
obtained LOD and LOQ values of nimesulide and impuri-
ties C and D confirmed the sensitivity of this method.
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tion to the primary amino group. Its polarity is lower com-
paring to nimesulide and it was eluted from the column
after nimesulide. The molecule of the impurity C has one
primary aromatic amino group and it was the most
lipophilic component of the analyzed mixture. So, having
the higher affinity for the binding at the stationary phase,
the impurity C had the longest retention time and was
eluted from the column at the end of chromatographic
procedure.
3. 2. Method Validation
Optimal chromatographic parameters were achieved
with the mobile phase consisting of acetonitrile – TEA –
water (45:0.5:54.5 v/v/v), pH adjusted to 5.2 with formic
acid, on an Agilent Zorbax Extend C18 column (150 × 4.6
mm, particle size 5 µm) at 40 °C. The pump operated in an
isocratic mode at a flow rate of 1.0 mL min–1. The UV-
detection was performed at 230 nm. Injections were car-
ried out using a 20 µL loop. Before each injection, the col-
umn was equilibrated to stable baseline at a flow rate of
1.0 mL min–1 and 40 °C. Representative chromatogram
obtained from working solutions of nimesulide and its im-
purities C and D is shown in Fig. c.
Under described conditions, RP-HPLC procedure
was performed. Optimal chromatographic parameters
such as retention time (tR), retention factor (k’ = tR – t0/t0),
symmetry factor (As = W0.05/2d), resolution (Rs =
1.18*(tR2 – tR1)/Wh1 + Wh2), separation factor (α = k2’/k1’),
Table 1. Chromatographic parameters of the described HPLC method (System suitability test).
Compound tR k' As Rs α N HETP
Nimesulide 7.11 4.21 0.928 3.20 1.15 10834.88 0.014
Impurity D 7.98 4.85 0.981 2.40 1.10 13673.37 0.011
Impurity C 8.66 5.35 0.955 13926.75 0.011
Figure c: Representative chromatogram obtained from working so-
lutions of nimesulide  (N, 0.1 mg mL–1) and its impurities (C and D
0.004 mg mL–1).
HPLC conditions: Mobile phase – acetonitrile – TEA – water
(45:0.5:54.5 v/v/v), pH 5.2 (adjusted with formic acid). Flow rate
1.0 mL min–1.
Figure d: Chromatogram of the excipients.
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Robustness of the analytical method was tested ap-
plying 23 full factorial design at two levels.40–42 The exper-
imental domain of the selected factors is shown in Table 3.
Resolutions of nimesulide and impurity D (Rs1,2)
and that of impurities D and C (Rs2,3), were choosen as the
response parameters. The design matrix of 23 factorial 
design shows eight treatment combinations of a low (–)
and high (+) level of the factors (Table 4).
The central point in the design, experiment No. 9,
was added only as a control to see whether there is a non-
linear relationship between the variables and the respons-
es. Traditional tabular presentation of the data for calcu-
lating the classic factor effects or coefficients in a 23 facto-
rial design for Rs1,2 and for Rs2,3 are given in Table 5.
The obtained values for the factor effects (Table 5)
indicate that the content of acetonitrile in the mobile
phase (factor A) and the pH of the mobile phase (factor B)
had the greatest impact on the chromatographic behavior
of the system. The two-factor and three-factor interactions
also expressed a strong influence. However, resolutions
Table 2. Validation parameters of the calibration curves, limits of detection and quantitation.
y – peak area; a – the slope; b – the intercept; x – concentration of the compound; r – correlation coefficient; Sa – standard deviation
of the slope; Sb – standard deviation of the intercept; tα – the confidence factor.
Compound Regression equation r Sa Sb tα LOD LOQ 
y = a*x + b (µg/mL) (µg/mL)
Nimesulide 39944.274*x + 54.906 0.9999 23.39 225.05 2.35 5.8
Impurity C 68.410*x – 0.027 0.9986 0.10 0.51 0.26 0.0044 0.0146
Impurity D 46.932*x – 0.069 0.9999 0.04 0.20 1.70 0.0026 0.0085
Factor Low Zero High 
(Chromatographic level level level 
variable) (–) (0) (+)
acetonitrile (%) 40 45 50
pH of the mobile phase 4.0 4.5 5.0
column temperature (°C) 30 35 40
Table 3. Chromatographic conditions and the range investigated
during method robustness testing.
No. Factor level Resolution Resolution 
A B C (Rs1,2) (Rs2,3)
1. – – – 2.81 0.00
2. + – – 2.79 1.71
3. – + – 2.84 0.00
4. + + – 2.93 2.57
5. – – + 2.87 0.00
6. + – + 2.95 2.24
7. – + + 2.80 0.00
8. + + + 2.93 2.98
9. 0 0 0 3.04 1.66
Table 4. Model matrix for 23 full factorial design with zero level.
Coefficients Estimates of factor Estimates of factor 




b1 b2 –0.039 –0.399
b3 –0.004 –0.233
b1b3 –0.034 –0.233
b2 b3 –0.064 –0.028
b1 b2 b3 –0.014 –0.028
Table 5. Estimates of factor effects (coefficients) for the resolution
of nimesulide and impurity D (Rs1,2) and impurities D and C (Rs2,3).
b0 – the intercept of the linear model or the mean value of the
considered response; b1, b2 and b3 – the main effects of factors; 
b12, b13 and b23 – the two-factor interactions; b123 – the three-factor
interactions
Rs1,2 and Rs2,3 were less sensitive to variations at the level
of temperature of the column (factor C). Based on the 
results of these experiments, the following theoretical
equation that correlates resolution between nimesulide
and impurity D (Rs1,2) with the most important chromato-
graphic conditions was derived:
Z = 53.884 – 1.934*x – 0.762*y + 0.025*x*x – 0.001*x
*y + 0.012*y*y
Figure e: 3D plot – The resolution Rs1,2 response to acetonitrile
content in the mobile phase (%) and temperature of the column
(°C) α = f (% ACN, t °C).
At lower pH values of the mobile phase, difference
in the availability of free electron pair on nitrogen atom
disappeared. Thus, the influence of (–)-mesomer effect of
nitro group in p-position in relation to the base of primary
aromatic amino group was reduced. An equal protonation
of the primary aromatic amino group in both analyzed
impurities led to the assimilation of their polarity and they
were eluted together, i.e. appeared as a single peak during
spectrophotometric recording.
Temperature increase potentiated the differences in
solubility of the examined compounds in polar mobile
phase used and this resulted in the differences of their
retention on nonpolar stationary phase.
Therefore, fine tuning of pH and acetonitrile con-
centration in the mobile phase can significantly improve
the separation of these three analytes. A satisfactory chro-
matographic behavior requires resolutions to be 1 < Rs <
10.7 Thus, good separation and optimum run time can be
assessed only with lower level of factor A and higher lev-
els of other investigated factors. The robustness of the
method was evident by the absence of overlapping peaks.
The precision of the chromatographic procedure
was investigated for three concentrations from the calibra-
tion plots of each nimesulide, impurity C and impurity D.
Analyzing seven solutions for the three chosen concentra-
tions from the calibration plots of each substance assessed
precision (repproducibility) of the chromatographic pro-
cedure. From the results listed in Table 6. it can be seen
that relative standard deviation values (RSD < 2% for acti-
ve ingredients and RSD < 5% for related compounds) and
reproducibility were satisfactory.43
Accuracy for the assay of nimesulide, impurity C
and impurity D was also investigated. The closeness of the
measured value to the true value for the sample (accuracy)
was assessed by analyzing a sample of known concentra-
tion and comparing the measured value to the true value.44
The accuracy results presented in Table 7. show satisfac-
tory values of mean recovery per concentration (98.0–
102.0% for active ingredients and 90.0–110.0% for relat-
ed compounds) and satisfactory accuracy of the system.43
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where x is the content of acetonitrile in the mobile phase
(%); y – temperature of the column (°C) and z – the reso-
lution of nimesulide and impurity D (Rs1,2). The 3D plot is
depicted in Fig. e.
The following theoretical equation correlating the
resolution of impurities D and C (Rs2,3) with the most 
important chromatographic conditions was derived:
Z = 35.323 + 0.337*x + 10.728*y + 0.001*x*
x – 0.05*x*y – 0.857*y*y
where x represents acetonitrile concentration in the mobi-
le phase (%); y is pH of the mobile phase, and z the reso-
lution of impurities C and D (Rs2,3). The 3D plot is depict-
ed in Fig. f.
Separation of the examined impurities was poor, be-
cause the difference in their solubility was lost in more
polarized mobile phase due to a low acetonitrile content.
Higher pH values of the mobile phase potentiated
the expression of (–)-mesomer effect of nitro group in 
p-position of impurity D. Because of this effect, the pri-
mary aromatic amino group of impurity D was protonated
to a lesser extent in relation to the aromatic amino group
of impurity C. Reduced protonation of the primary aro-
matic amino group in impurity D led to a decrease of ion-
ization level of the molecule and consequently, to decrea-
sed solubility of this component in polar mobile phase and
its increased retention on the column. However, at higher
pH values of the mobile phase, impurity C was ionized to
a lesser extent than at lower pH values and as a result of
decreased hydrogen ion concentration, polarity of this
impurity was also reduced. Under these conditions, a bet-
ter separation of the impurities was achieved than at lower
pH values of the mobile phase.
Figure f: 3D plot – The resolution Rs2,3 response to acetonitrile
concentration in the mobile phase (%), and pH of the mobile phase 
α = f (% ACN, pH). Compound Concentration SD RSD (%)
Nimesulide 0.08 1.59 0.05
(mg mL–1) 0.12 6.06 0.05
0.16 13.07 0.20
Impurity C 0.05 0.02 0.44
(µg mL–1) 0.21 0.12 0.82
0.33 0.10 0.45
Impurity D 0.05 0.04 1.64
(µg mL–1) 0.20 0.12 1.26
0.33 0.10 0.68
Table 6. Precision of the assay expressed as RSDs of seven sam-
ples in three concentrations.
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The developed HPLC method is sensitive and speci-
fic for the quantitative determination of nimesulide and its
impurities C and D. Also, the method has been applied for
the estimation of nimesulide drugs in five different solid
pharmaceutical dosage forms. A typical chromatogram
including nimesulide for the test assay is presented in Fig.
g.
Nimesulide tablets containing 100 mg of the active
substance produced by five different manufacturers as
given under Material and methods section, were evalu-
ated for the content of nimesulide and its impurities C 
(2-phenoxyaniline) and D (2-phenoxy-4-nitroaniline)
present in the formulations. Each sample was analyzed in
triplicate after the extraction. The amount of nimesulide
found by the described procedure is given in Table 8.
The testing tablets had impurities under the limit of
detection of this method.
4. Conclusions
A simple, rapid, sensitive and accurate RP-HPLC
method for simultaneous determination of nimesulide and
its impurities C and D in five different solid pharmaceuti-
cal formulations has been developed. The proposed
method can be used for monitoring the stability of nime-
sulide in pharmaceutical dosage forms, as well. The run
time of 10 min and flow rate of 1.0 mL min–1 allows the
analysis of a large number of samples with less mobile
phase. The method is efficient and sensitive means to de-
termine nimesulide and its main impurities C and D with
no interference of excipients present in the pharmaceuti-
cals demonstrating a high selectivity of this procedure.
The method can be successfully used in the quality con-
trol, as well as purity and stability testing.
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Povzetek
Opisujemo enostavno in hitro metodo za dolo~itev nimesulida in ne~isto~ v farmacevtskih pripravkih z dobro ponovlji-
vostjo. Metoda je uporabna za sledenje stabilnosti. Dolo~ili smo prisotnost dveh ne~isto~: C (2-fenoksianilin) in D (2-
fenoksi-4-nitroanilin). Najbolj{o lo~itev smo dosegli z uporabo kolone Agilent Zorbax Extend C18 (150 × 4,6 mm, ve-
likost delcev 5 µm) pri 40 °C in pretoku 1,0 mL min–1. Uporabili smo UV detekcijo pri 230 nm. Mobilna faza je bila iz
acetonitrila – trietilamina (TEA) – vode (45:0,5:54,5 v/v/v), s pH 5,2, kar smo dosegli z dodatkom mravlji~ne kisline.
Pod temi pogoji so bili retencijskih ~asi 7,11, 7,98 in 8,66 min za nimesulid, D in C z dobro lo~itvijo. Evaluirali smo li-
nearnost, to~nost, pravilnost, selektivnost, ob~utljivost in robustnost metode in jo uporabili za dolo~itev nimesulida v
razli~nih farmacevtskih pripravkih.
